Twist Bioscience (NASDAQ:TWST) CAO Robert Werner Sells 148 Shares of Company Stock

Twist Bioscience Corporation (NASDAQ:TWST) CAO Robert Werner sold 148 shares of the firm’s stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $135.40, for a total value of $20,039.20. Following the completion of the transaction, the chief accounting officer directly owned 42,769 shares in the company, valued at $5,790,922.60. The trade was a 0.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Twist Bioscience Trading Down 15.4%

Twist Bioscience stock opened at $120.61 on Friday. The business has a 50-day simple moving average of $152.00 and a two-hundred day simple moving average of $90.68. The company has a market cap of $7.56 billion, a P/E ratio of -54.33 and a beta of 2.25. Twist Bioscience Corporation has a 52-week low of $23.30 and a 52-week high of $219.71. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.05). The business had revenue of $118.38 million for the quarter, compared to analysts’ expectations of $114.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. Twist Bioscience’s revenue for the quarter was up 23.2% compared to the same quarter last year. During the same period in the previous year, the company earned $0.33 EPS. Analysts predict that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Key Twist Bioscience News

Here are the key news stories impacting Twist Bioscience this week:

• Positive Sentiment: Twist Bioscience has launched MRD Express, a development that could support its presence in the minimal residual disease testing market. The article also notes the stock is entering earnings week, when investors may look for updates on the product and business outlook. Read More.
• Neutral Sentiment: A separate analysis describes an “undervalued” investment narrative but flags the company’s sales valuation as expensive, presenting a mixed view rather than a clear near-term catalyst. Read More.
• Neutral Sentiment: Four executives and insiders, including CEO Emily M. Leproust, sold a combined 6,677 shares at $135.40. The transactions were reported as covering tax withholding obligations related to equity-award vesting, which makes them less indicative of discretionary selling.
• Negative Sentiment: Shares fell amid a negative report from The Bear Cave/Hunterbrook. The available headline does not detail the report’s claims, but the coverage appears to have weighed on investor sentiment. Read More.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. UBS Group started coverage on shares of Twist Bioscience in a research report on Wednesday, September 9th. They set a “neutral” rating and a $144.00 price objective on the stock. Leerink Partners upped their target price on shares of Twist Bioscience from $160.00 to $190.00 and gave the stock an “outperform” rating in a report on Tuesday, September 29th. Piper Sandler increased their price target on Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 5th. Barclays raised their price target on Twist Bioscience from $112.00 to $215.00 and gave the company an “overweight” rating in a report on Wednesday, October 7th. Finally, TD Cowen boosted their price objective on Twist Bioscience from $115.00 to $190.00 and gave the company a “buy” rating in a research report on Tuesday, October 13th. Seven investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $153.00.

Hedge Funds Weigh In On Twist Bioscience

Hedge funds and other institutional investors have recently modified their holdings of the stock. Abacus Wealth Partners LLC lifted its position in Twist Bioscience by 4.3% during the third quarter. Abacus Wealth Partners LLC now owns 2,332 shares of the company’s stock valued at $451,000 after purchasing an additional 96 shares during the last quarter. Root Financial Partners LLC purchased a new position in shares of Twist Bioscience in the 3rd quarter worth $33,000. GAMMA Investing LLC increased its holdings in shares of Twist Bioscience by 24.4% in the 2nd quarter. GAMMA Investing LLC now owns 943 shares of the company’s stock worth $97,000 after buying an additional 185 shares during the last quarter. Abel Hall LLC increased its holdings in shares of Twist Bioscience by 3.6% in the 3rd quarter. Abel Hall LLC now owns 5,514 shares of the company’s stock worth $1,066,000 after buying an additional 191 shares during the last quarter. Finally, Allworth Financial LP increased its holdings in shares of Twist Bioscience by 54.9% in the 2nd quarter. Allworth Financial LP now owns 601 shares of the company’s stock worth $62,000 after buying an additional 213 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA and related products for life sciences research. The company uses a proprietary silicon-based platform to produce high-quality DNA at scale, supporting applications in synthetic biology, drug discovery and development, agriculture, and academic and industrial research.

Its offerings include synthetic genes, oligonucleotides, gene fragments, variant libraries, and antibody discovery products.